Methylated Septin9 as an auxiliary biomarker for the diagnostic, recurrence monitoring and prognosis of colorectal cancer.
Blood tests detecting a modified DNA marker help track colorectal cancer recurrence and predict outcomes alongside standard surveillance methods.
This study evaluates methylated Septin9 as a blood-based biomarker for colorectal cancer, showing its utility across diagnosis, recurrence detection, and prognosis assessment. The cfDNA-based marker adds value as an auxiliary tool alongside standard CRC surveillance methods.
What the study was
- Study design
- Diagnostic biomarker study
- Population
- Colorectal cancer patients
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinica chimica acta
Why it surfaced
Established biomarker (mSEPT9) with incremental validation. Not novel but confirms clinical utility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.